Infinity Bio To Host Open House at State-of-the-Art Laboratory

Company offers cutting-edge solutions and services to pharma, academia, and the greater biomedical research community.

BALTIMORE--(BUSINESS WIRE)--Infinity Bio, a technology company known for its innovative antibody reactome profiling service, will host an open house event at its state-of-the-art laboratory at 6200 Seaforth Street in Baltimore on July 23, 2024. This event is designed to give members of the local scientific and biotech community an exclusive look at the research and technologies that are driving developments in immunology.

Infinity Bio, founded in 2023, utilizes its proprietary MIPSA technology to perform advanced antibody reactivity profiling, providing deep insights that are crucial for developing next-generation therapeutics and diagnostics. The company’s core technology comprehensively measures the antibody reactome, revealing the targets of individual immune responses against all known human viruses, human proteins (autoimmunity), and allergen proteins. Developed at Johns Hopkins University in Dr. H. Benjamin Larman's Laboratory of Precision Immunology, Infinity Bio’s assay builds off decades of work in genomics, proteomics, immunology, and bioinformatics, ensuring best-in-class turnaround times and cost efficiency. Larman also serves as Infinity Bio’s Chief Science Officer.

The event will include live demonstrations of sample processing through their state-of-the-art automation system, Q&A sessions with Infinity Bio’s researchers, and a preview of informatics reporting. Attendees will also have the chance to network with other professionals in the field.

“We are eager to showcase our laboratory, commitment to quality, and our team,” says Joy M. Nassif, CEO of Infinity Bio. “Our team is dedicated to the pursuit of scientific excellence and customer delight, and we believe that transparency and collaboration are key to driving innovation.”

Larman states: “The open house will be a unique opportunity for researchers in academia and biotech to learn about our industry leading antibody reactome profiling services, and to see for themselves how Infinity Bio can transform their immunology research.”

To register for the open house, please visit https://www.infinitybio.com/open-house-rsvp.

ABOUT INFINITY BIO
Infinity Bio, Inc. is a technology company that provides detailed insights into the immune system using its proprietary antibody profiling platform. The company’s core technology comprehensively measures the antibody reactome, revealing the targets of individual immune responses against all known human viruses, human proteins (autoimmunity), and allergen proteins. Infinity's assay, MIPSA, was developed at Johns Hopkins University in Dr. H. Benjamin Larman's Laboratory of Precision Immunology. It builds off of decades of work in the fields of genomics, proteomics, immunology, and bioinformatics. Our assay was engineered to enable best-in-class turnaround times and core to our values are quality and customer delight.